How to measure proteinuria?

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 6, 2008, Pages 600-603

  McIntyre, Natasha J ^a   Taal, Maarten W ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Albumin to creatinine ratio; Albuminuria; Chronic kidney disease; Protein to creatinine ratio

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PROTEIN;

CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MICROALBUMINURIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ALBUMINURIA; CHRONIC DISEASE; CREATININE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINURIA;

EID: 56249091115     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328313675c     Document Type: Review

References (34)

1. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73:1216-1219.
2. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 2001; 60:1131-1140.
3. Ruggenenti P, Pema A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63:2254-2261.
4. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study group. N Engl J Med 1994; 330:877-884.
5. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
6. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
7. Ruggenenti P, Pema A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354:359-364.
8. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354:131-140.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
10. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
11. Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18:1959-1965.
12. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18:1889-1898.
13. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543-1546.
14. Rodby RA, Rohde RD, Sharon Z, et al. The urine protein to creatinine ratio as a predictor of 24-h urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study group. Am J Kidney Dis 1995; 26:904-909.
15. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 h urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998; 316:504-509.
16. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147:943-944.
17. Chitalia VC, Kothari J, Wells EJ, et al. Cost-benefit analysis and prediction of 24-h proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol 2001; 55:436-447.
18. Antunes VV, Veronese FJ, Morales JV. Diagnostic accuracy of the protein/creatinine ratio in urine samples to estimate 24-h proteinuria in patients with primary glomerulopathies: a longitudinal study. Nephrol Dial Transplant 2008; 23:2242-2246.
19. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
20. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
21. Chaiken RL, Khawaja R, Bard M, et al. Utility of untimed urinary albumin measurements in assessing albuminuria in black NIDDM subjects. Diabetes Care 1997; 20:709-713.
22. Marshall SM. Screening for microalbuminuria: which measurement? Diabet Med 1991; 8:706-711.
23. Gansevoort RT, Verhave JC, Hillege HL, et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005; 94:828-335.
24. Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant 2007; 22:2194-2200.
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
26. Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study. Clin J Am Soc Nephrol 2006; 1:761-767.
27. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47:1-7.
28. Burden RP, Thomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines. Clin Med 2005; 5:635-642.
29. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of chronic kidney disease. 2008. http://www.sign.ac.uk/guidelines/ fulltext/103/index.html. [Accessed 1 Aug 2008].
30. Caring for Australians with Renal Impairment (CARI). Urine protein as a diagnostic test. 2004. http://www.cari.org.au/ckd_urineprot_list_pub2004. php. [Accessed 1 Aug 2008].
31. Kidney Disease Quality Outcomes Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49:S12-S154.
32. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant 2003; 18:2170-2174.
33. MacGregor MS, Traynor JP, O'Reilly DS, Delghan CJ. Comparison of protein:creatinine and albumin:creatinine ratio in chronic kidney disease [abstract]. British Renal Society and Renal Association Abstracts 2008: 200. https://registrations-online.com/Renal2008/docs/Uploaded/Posters/P16%20M.
34. Ohisa N, Yoshida K, Matsuki R, et al. A comparison of urinary albumin-total protein ratio to phase-contrast microscopic examination of urine sediment for differentiating glomerular and nonglomerular bleeding. Am J Kidney Dis 2008; 52:235-241.